Literature DB >> 17242281

Quantifying improvement in symptoms, functioning, and quality of life after peripheral endovascular revascularization.

David M Safley1, John A House, Steven B Laster, William C Daniel, John A Spertus, Steven P Marso.   

Abstract

BACKGROUND: Patients with peripheral arterial disease often undergo peripheral endovascular revascularization (PER) to alleviate symptoms. Despite the growth of PER, little information exists quantifying the health status benefits after the procedure. METHODS AND
RESULTS: From February 2001 to August 2004, 477 consecutive patients underwent PER for symptomatic peripheral arterial disease. Of these, 300 consented to participate in a longitudinal follow-up study of their health status. Health status was quantified with the disease-specific Peripheral Artery Questionnaire and the generic Short Form-12 and the EuroQol 5 Dimensions (EQ5D)questionnaire. Scores range from 0 to 100; higher scores represent fewer symptoms and better health status. The average age of the cohort was 68+/-11 years (mean+/-SD); 186 (62%) were male, 288 (96%) were white, and 118 (39%) were diabetic. Clinical follow-up was attained in 99% of patients; health status assessments were made in 86%. Mean Peripheral Artery Questionnaire summary scores improved significantly after revascularization from 31+/-19 to 62+/-27 at 1 year (P<0.0001). Generic health status scores also improved significantly (P<0.001 for all). Despite a technically successful procedure in 98% of patients, 21% of patients did not achieve the minimal clinically important improvement of an 8-point change in Peripheral Artery Questionnaire Summary score after PER (35+/-19 at baseline versus 31+/-16 at 1 year; P=0.09).
CONCLUSIONS: For most patients, significant and sustained improvements in symptoms, functioning, and quality of life occur after PER. Identifying and counseling patients less likely to benefit from PER is an important future research direction.

Entities:  

Mesh:

Year:  2007        PMID: 17242281     DOI: 10.1161/CIRCULATIONAHA.106.643346

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Understanding sex differences in health status: A frontier in the field of vascular medicine.

Authors:  Ryan J Mays; Judith G Regensteiner
Journal:  Vasc Med       Date:  2017-03-14       Impact factor: 3.239

2.  Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease.

Authors:  Scott Kinlay
Journal:  Circulation       Date:  2013-03-19       Impact factor: 29.690

3.  Correlation of patient-reported symptom outcomes and treadmill test outcomes after treatment for aortoiliac claudication.

Authors:  Timothy P Murphy; Matthew R Reynolds; David J Cohen; Judith G Regensteiner; Joseph M Massaro; Donald E Cutlip; Emile R Mohler; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Suzanne Goldberg; Alan T Hirsch
Journal:  J Vasc Interv Radiol       Date:  2013-07-29       Impact factor: 3.464

Review 4.  Assessment of functional status and quality of life in claudication.

Authors:  Ryan J Mays; Ivan P Casserly; Wendy M Kohrt; P Michael Ho; William R Hiatt; Mark R Nehler; Judith G Regensteiner
Journal:  J Vasc Surg       Date:  2011-02-18       Impact factor: 4.268

5.  Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study.

Authors:  Timothy P Murphy; Donald E Cutlip; Judith G Regensteiner; Emile R Mohler; David J Cohen; Matthew R Reynolds; Joseph M Massaro; Beth A Lewis; Joselyn Cerezo; Niki C Oldenburg; Claudia C Thum; Suzanne Goldberg; Michael R Jaff; Michael W Steffes; Anthony J Comerota; Jonathan Ehrman; Diane Treat-Jacobson; M Eileen Walsh; Tracie Collins; Dalynn T Badenhop; Ulf Bronas; Alan T Hirsch
Journal:  Circulation       Date:  2011-11-16       Impact factor: 29.690

6.  Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease Questionnaire.

Authors:  Poghni A Peri-Okonny; Jingyan Wang; Kensey L Gosch; Manesh R Patel; Mehdi H Shishehbor; David L Safley; J Dawn Abbott; Herbert D Aronow; Carlos Mena-Hurtado; Qurat-Ul-Ain Jelani; Yuanyuan Tang; Matthew Bunte; Clementine Labrosciano; John F Beltrame; John A Spertus; Kim G Smolderen
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2021-05-05

7.  Physical Activity After Treatment for Symptomatic Peripheral Artery Disease.

Authors:  Poghni A Peri-Okonny; Sarthak Patel; John A Spertus; Elizabeth A Jackson; Ali O Malik; Jeremy Provance; Carlos Mena-Hurtado; Mehdi H Shishehbor; Vittal Hijjaji; Kensey L Gosch; Kim G Smolderen
Journal:  Am J Cardiol       Date:  2020-10-13       Impact factor: 2.778

8.  Gender differences in health status and adverse outcomes among patients with peripheral arterial disease.

Authors:  Rachel P Dreyer; Moniek van Zitteren; John F Beltrame; Robert Fitridge; Johan Denollet; Patrick W Vriens; John A Spertus; Kim G Smolderen
Journal:  J Am Heart Assoc       Date:  2014-12-23       Impact factor: 5.501

9.  Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial.

Authors:  Matthew R Reynolds; Patricia Apruzzese; Benjamin Z Galper; Timothy P Murphy; Alan T Hirsch; Donald E Cutlip; Emile R Mohler; Judith G Regensteiner; David J Cohen
Journal:  J Am Heart Assoc       Date:  2014-11-11       Impact factor: 5.501

Review 10.  A review of health utilities using the EQ-5D in studies of cardiovascular disease.

Authors:  Matthew T D Dyer; Kimberley A Goldsmith; Linda S Sharples; Martin J Buxton
Journal:  Health Qual Life Outcomes       Date:  2010-01-28       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.